2023-01-01 - 2029-05-19
Phase III
召募中7
ICD-10C33
氣管惡性腫瘤
ICD-10Z51.12
來院接受抗腫瘤免疫療法
ICD-9162.0
氣管惡性腫瘤
一項第3期隨機分配、開放性臨床試驗，在患有轉移性非小細胞肺癌受試者的第一線治療中合併施用化學治療，評估皮下注射Pembrolizumab與Hyaluronidase之複方（MK-3475A）相較於靜脈注射Pembrolizumab的藥物動力學和安全性
-
試驗申請者
美商默沙東藥廠股份有限公司台灣分公司
-
試驗委託 / 贊助單位名稱
美商默沙東藥廠股份有限公司台灣分公司
-
臨床試驗規模
多國多中心
-
更新日期
2026/02/01
試驗主持人及試驗醫院
實際收案人數
0 召募中
實際收案人數
0 召募中
實際收案人數
0 召募中
實際收案人數
0 召募中
實際收案人數
0 召募中
實際收案人數
0 召募中
適應症
試驗目的
藥品名稱
注射劑
主成份
Pembrolizumab (Humanized anti-PD-1 mAb)
劑型
Injection
劑量
100 mg/4 mL/vial
評估指標
(2)穩定態（第3 週期）C trough
主要納入條件
可能有一些原因會使您無法參加本試驗，試驗醫師或人員將與您討論這些原因。
將有約339人參與本試驗。
主要排除條件
Has a diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements.
Has received prior systemic anticancer therapy for metastatic NSCLC.
Has received prior systemic anticancer therapy including investigational agents within 4 weeks before randomization.
Has received prior radiotherapy within 2 weeks of start of study intervention or has radiation-related toxicity requiring corticosteroids.
Has received radiation therapy to the lung (>30 Gray) within 6 months of start of study intervention.
Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention.
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy.
Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.
Has an active autoimmune disease that has required systemic treatment in past 2 years.
Has an active infection requiring systemic therapy.
Has a history of human immunodeficiency virus (HIV) infection.
Has a history of Hepatitis B or C.
Has not adequately recovered from major surgery or has ongoing surgical complications.
Has a history of allogenic tissue/solid organ transplant.
試驗計畫預計收納受試者人數
-
台灣人數
28 人
-
全球人數
378 人
